

## REMARKS

### Response to Restriction Requirement

In response to the Restriction Requirement, Applicants hereby elect to prosecute claims directed to Group II: methods for treating a cardiovascular disease comprising administration of an AA<sub>1</sub>RA and a beta blocker. Applicants elect heart failure as a species of cardiovascular disease, KW-3902 as a species of AA<sub>1</sub>RA, and carvedilol as a species of beta blocker. Claims that read on this species include Claims 10-13, 26-32 and 34. Pursuant to M.P.E.P. §809.02(a), Applicants understand that upon a finding that the generic claim is allowable, Applicants will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitation of the generic claims.

### No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, the Applicants are not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. The Applicants reserve the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that the Applicants have made any disclaimers or disavowals of any subject matter supported by the present application.

Application No.: 10/785,446  
Filing Date: February 23, 2004

### CONCLUSION

The undersigned has made a good faith effort to respond to the Restriction Requirement. Nevertheless, if any undeveloped issues remain or if any issues requires clarification, the Examiner is invited to call the undersigned attorney to resolve such issues promptly.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 11, 2008

By: Kathleen R. Mekjian  
Kathleen R. Mekjian  
Registration No. 61,399  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

4937764  
022608